<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-688" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Herpes Simplex Type 2</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mathew Jr</surname>
            <given-names>Jacob</given-names>
          </name>
          <aff>Parkview Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sapra</surname>
            <given-names>Amit</given-names>
          </name>
          <aff>Southern Illinois University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jacob Mathew Jr declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amit Sapra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-688.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>This activity reviews the evaluation and management of herpes simplex type 2 and highlights the role of the primary care provider in managing patients with this condition. In addition to providing basic knowledge of the condition and clinical presentation of herpes genitalis, this review will highlight important aspects of diagnostic interventions, antiviral therapy (both current and future), and prophylaxis. This activity covers the interprofessional team managing patients with herpes genitalis and the potential of being exposed to herpes genitalis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of herpes simplex type 2.</p></list-item><list-item><p>Outline the appropriate evaluation of herpes simplex type 2.</p></list-item><list-item><p>Review the treatment and management options available for herpes simplex type 2.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance herpes simplex type 2 and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=688&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=688">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-688.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Herpes genitalis can be caused by the herpes simplex virus type 1 or 2, manifesting as a primary or recurrent infection.<xref ref-type="bibr" rid="article-688.r1">[1]</xref>&#x000a0;&#x000a0;Most commonly, viral replication occurs in epithelial tissue and establishes dormancy in sensory neurons, reactivating periodically as localized recurrent lesions.<xref ref-type="bibr" rid="article-688.r2">[2]</xref>&#x000a0;&#x000a0;It remains one of the most common sexually transmitted infections (STI) but continues to be underestimated, given the vague presentation of its symptoms.<xref ref-type="bibr" rid="article-688.r3">[3]</xref>&#x000a0;In addition to providing the reader with basic knowledge of the pathogen and clinical presentation of herpes genitalis, this review article discusses important aspects of laboratory diagnostics, antiviral therapy, and prophylaxis. This article is aimed at all healthcare providers managing patients with herpes genitalis and attempts to improve the often suboptimal counseling and targeted use of laboratory diagnostics, treatment, and preventive measures provided to patients.</p>
        <p>Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone.<xref ref-type="bibr" rid="article-688.r4">[4]</xref>&#x000a0;While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most infection outbreaks will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed.<xref ref-type="bibr" rid="article-688.r4">[4]</xref>&#x000a0;As a result, further exposure to uninfected individuals may occur.</p>
      </sec>
      <sec id="article-688.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Risk factors for acquiring HSV-2 infection involve direct exposure to fluids (i.e., saliva) from a seropositive individual containing viral products, most often during sexual intercourse.<xref ref-type="bibr" rid="article-688.r3">[3]</xref>&#x000a0;HSV-2 is mainly transmitted through sexual intercourse, attributing to its predominant rise starting at puberty.<xref ref-type="bibr" rid="article-688.r3">[3]</xref>&#x000a0;Due to its low stability outside the body, HSV can only remain infectious for days on moist surfaces. Therefore, modes of transmission other than sexual intercourse are often insignificant.<xref ref-type="bibr" rid="article-688.r3">[3]</xref>&#x000a0;Both primary and recurrent HSV infections in pregnant women can lead to intrauterine transmission and resultant congenital HSV infection.<xref ref-type="bibr" rid="article-688.r5">[5]</xref></p>
      </sec>
      <sec id="article-688.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Herpes genitalis remains among the most common sexually transmitted infections (STI).<xref ref-type="bibr" rid="article-688.r3">[3]</xref>&#x000a0;While the majority of cases are due to HSV-2, rare but increasing cases have been found due to herpes simplex virus type 1 (HSV-1).<xref ref-type="bibr" rid="article-688.r3">[3]</xref>&#x000a0;The primary mode of transmission of both HSV-1 and HSV-2 is via direct contact with open lesions. Sixteen percent of patients aged 14 to 49 were reported to be seropositive for HSV-2 from 2005 to 2010.<xref ref-type="bibr" rid="article-688.r6">[6]</xref>&#x000a0;Antibodies to HSV-2 are often present by the time of puberty, and their presence often correlates with the degree of sexual activity of that individual. More women than men have been reported to be infected, and as expected, the prevalence increases with an increasing number of sexual partners.&#x000a0;<xref ref-type="bibr" rid="article-688.r7">[7]</xref>&#x000a0;Ethnically, non-Hispanic African Americans have greater rates of infection than non-Hispanic Whites. About 85% to 90% of infections are unrecognized and remain undiagnosed.<xref ref-type="bibr" rid="article-688.r8">[8]</xref></p>
        <p>In the United States, HSV remains one of the most common causes of genital ulcers; internationally, more than 23 million new cases are reported annually.<xref ref-type="bibr" rid="article-688.r9">[9]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-688.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>HSV-2 is transmitted through direct contact with secretions in a seropositive individual who is actively shedding the virus. The virus preferentially affects the skin and mucous membranes, invading epithelial cells on initial exposure and ultimately replicating intracellularly at that site. After the initial exposure and symptoms resolve, in 10 to 14 days, on average, the virus then lays dormant in the periaxonal sheath of the sensory nerves of either the trigeminal, cervical, lumbosacral, or autonomic ganglia. In these locations, the viral replication is often controlled by the patient's immune system and remains dormant, only to reactivate later in life.<xref ref-type="bibr" rid="article-688.r9">[9]</xref>&#x000a0;When reactivation does occur, the virus travels through the sensory nerves until it reaches the mucocutaneous sites, where replication then takes place and leads to vesicular clusters at the dermatological site of that sensory neuron.</p>
      </sec>
      <sec id="article-688.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histological presentations of HSV-2 include the presence of dense lymphoid infiltrates with atypical lymphocytes.<xref ref-type="bibr" rid="article-688.r10">[10]</xref>&#x000a0;Diagnosis is often made based on the clinical exam, but if the pathological analysis is performed, it is consistent with dense and deep infiltrates of lymphocytes near adnexal structures along with individual necrotic keratinocytes. When looking at the surface of cells, it is common to see epidermal ballooning and acantholysis, which leads to the classic vesiculation seen on the clinical exam.<xref ref-type="bibr" rid="article-688.r11">[11]</xref>&#x000a0;Multinucleated giant cells and epithelial cells containing eosinophilic intranuclear inclusion bodies are seen on biopsies.</p>
      </sec>
      <sec id="article-688.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Genital symptoms are commonly seen in the outpatient primary care setting despite many going without a clear diagnosis. HSV-2, in particular, may present as a primary infection with painful&#x000a0;genital ulcers, sores, crusts, tender lymphadenopathy, and dysuria.<xref ref-type="bibr" rid="article-688.r4">[4]</xref>&#x000a0;The classical features are macular or papular skin and mucous membrane lesions progressing to vesicles and pustules that often last up to 3 weeks. Genital lesions can be especially painful, leading to swelling of the vulva in women, burning pain, and dysuria.<xref ref-type="bibr" rid="article-688.r12">[12]</xref></p>
        <p>It is important to note that HSV-2 does not typically present with painless&#x000a0;ulcers. Systemic symptoms can occur, including fever, headache, and malaise, and are often due to concurrent viremia, which has been reported in up to 24% of patients in one study.<xref ref-type="bibr" rid="article-688.r13">[13]</xref></p>
      </sec>
      <sec id="article-688.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>&#x000a0;<bold>Laboratory Assessments</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>A direct swab of vesicular lesions (within 72 hours of onset) is ideal, but avoid lesions that have evidence of crusting or healing. Do not clean the area with topical alcohols before acquiring the material.</p>
          </list-item>
          <list-item>
            <p>Swab locations include: skin via unroofing vesicles with a sterile needle, urethra via sterile swab, the cervix through the vaginal speculum, urine, swabbing of the conjunctiva, and rectal swabs through proctoscopes&#x000a0;<xref ref-type="bibr" rid="article-688.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>HSV PCR (if a direct swab is not possible, PCR is the test of choice)</p>
          </list-item>
          <list-item>
            <p>Tzank smear - low sensitivity and cannot decipher between HSV serotypes</p>
          </list-item>
          <list-item>
            <p>Direct fluorescent antigen</p>
          </list-item>
          <list-item>
            <p>HSV serotyping</p>
          </list-item>
          <list-item>
            <p>Antibody testing&#x000a0;<bold><xref ref-type="bibr" rid="article-688.r15">[15]</xref><xref ref-type="bibr" rid="article-688.r16">[16]</xref></bold></p>
          </list-item>
        </list>
        <p>&#x000a0;Given symptoms can mimic acute urinary tract infection, consider urinalysis and culture.</p>
        <p>&#x000a0;Given HSV is a sexually transmitted infection (STI), consider further STI workup to include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gonorrhea/chlamydia testing (urine)</p>
          </list-item>
          <list-item>
            <p>HIV (known interaction between HSV-2 and HIV in which concurrent infection may occur faster than if HSV-2 was not present)</p>
          </list-item>
          <list-item>
            <p>RPR</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-688.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of genital herpes centers around preventing its transmission and suppressing viral shedding through antiviral therapy and counseling regarding the risk of sexual transmission.&#x000a0;</p>
        <p>
<bold>Primary Treatment</bold>
</p>
        <p>Primary infections with multiple ulcerating lesions will resolve after approximately 19 days, regardless of treatment interventions.<xref ref-type="bibr" rid="article-688.r12">[12]</xref>&#x000a0;Treatments are typically categorized as either primary or non-primary. Primary infection is when the individual is experiencing their first outbreak (previously seronegative for HSV). Secondary (or non-primary) is an infection in a patient with preexisting immunity. Treatment is similar for both patient populations.&#x000a0;</p>
        <p>Antiherpesviral agents include those that act as nucleoside analog-polymerase inhibitors and pyrophosphate analog&#x02013;polymerase inhibitors. The mainstay of therapy remains acyclovir, which has antiviral activity against all herpesviruses and has been FDA-approved for treating and suppressing both HSV and VZV.<xref ref-type="bibr" rid="article-688.r17">[17]</xref>&#x000a0;Other treatments include penciclovir (which is more often used as a topical therapy for HSV labialis) and ganciclovir (which has suppression activity against CMV). These medications are preferentially taken up by those cells already infected with the virus and stop viral replication.&#x000a0;<xref ref-type="bibr" rid="article-688.r17">[17]</xref>&#x000a0;Treatment should be offered to all patients to prevent a prolonged duration of their symptoms, ideally immediately after the appearance of the first lesion.<xref ref-type="bibr" rid="article-688.r1">[1]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Acyclovir: available in topical, oral, and IV formulations. The oral formulation has quite a poor bioavailability, which has been improved with valacyclovir (see below). The benefits of acyclovir include its low side effect profile, which allows it to be tolerated for long periods. Suppressive treatment with acyclovir can prevent or delay up to 80% of recurrences, thus reducing shedding by greater than 90%.<xref ref-type="bibr" rid="article-688.r18">[18]</xref>&#x000a0;Reported side effects include kidney toxicity and neutropenia when given at high doses.<xref ref-type="bibr" rid="article-688.r17">[17]</xref>&#x000a0;Given its chronicity of use, resistance has been reported in immunocompromised patients and those who are immunocompetent taking acyclovir as suppressive therapy for genital herpes.<xref ref-type="bibr" rid="article-688.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Primary herpes genitalis: 3 x 400 mg tablets PO daily for 7 to 10 days</p>
              </list-item>
              <list-item>
                <p>Severe primary herpes genitalis: 3 x 5 mg/kg IV daily for 5 to 7 days</p>
              </list-item>
              <list-item>
                <p>Recurrent herpes genitalis (less than 5 to 6 episodes/year): 400 mg PO twice a day for 3 days&#x000a0;</p>
              </list-item>
              <list-item>
                <p>Prophylaxis: 2 x 400 mg PO daily for 6 months</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Valacyclovir is another formulation option that is attractive to patients</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Primary herpes genitalis: 2 x 500 mg tablets PO daily for 7 to 10 days</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Recurrent herpes genitalis (less than 5 to 6 episodes/year): 2 x 500 mg PO twice daily for 3 days</p>
          </list-item>
          <list-item>
            <p>or</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>1 x 1000 mg tablet daily for 5 days&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Prophylaxis: 1 x 500 mg PO daily for 6 months</p>
        <p>
<bold>Treatments on the Horizon</bold>
</p>
        <p>Standard therapy for herpes simplex virus type 2 infections includes acyclovir and valacyclovir. Medications on the horizon include brincidofovir and maribavir (both against CMV) and valomaciclovir (activity against HSV, VZV, and EBV). As patients seek alternative treatments with a smaller adverse effect profile, essential oils have been a focus of interest.<xref ref-type="bibr" rid="article-688.r19">[19]</xref>&#x000a0;HSV has demonstrated susceptibility to many essential oils and their constituents through both direct virucidal activity and inhibition of intracellular replication.<xref ref-type="bibr" rid="article-688.r19">[19]</xref>&#x000a0;Topical peppermint oil has been studied due to its virucidal component, with antiviral activity reported at 99% after only 3 hours of exposure.<xref ref-type="bibr" rid="article-688.r20">[20]</xref>&#x000a0;However, the stipulation of use and activity was that peppermint oil was only effective against the virus before absorption into the host cell. As a result, it may be of particular benefit from a chronic suppressive treatment rather than post-infectious symptoms. Other oils found to have antiviral effects against HSV include Australian tea tree oil and eucalyptus oil.<xref ref-type="bibr" rid="article-688.r21">[21]</xref></p>
        <p>
<bold>Vaccinations</bold>
</p>
        <p>HSV vaccines are being studied to reduce the severity of symptoms and to help expedite visible lesion healing. Furthermore, by reducing shedding, the severity may be reduced, as has been seen with the Varicella-zoster vaccination.<xref ref-type="bibr" rid="article-688.r2">[2]</xref>&#x000a0;No current vaccine is available for HSV.</p>
      </sec>
      <sec id="article-688.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>&#x000a0;Infectious genital ulcerative&#x000a0;conditions&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>
<list list-type="bullet"><list-item><p>Syphilis</p></list-item><list-item><p>Chancroid</p></list-item><list-item><p>Lymphogranuloma venereum</p></list-item><list-item><p>Granuloma inguinale</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Non-infectious genital ulcerative conditions
<list list-type="bullet"><list-item><p>Crohn disease</p></list-item><list-item><p>Behcet syndrome</p></list-item><list-item><p>Fixed drug eruptions</p></list-item><list-item><p>Psoriasis</p></list-item><list-item><p>Sexual trauma</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>&#x000a0;Genital HSV-2 infection is associated with an increased risk of HIV infection. As a result, be aware that testing for HIV infection may alter the treatment of HSV-2.<xref ref-type="bibr" rid="article-688.r22">[22]</xref></p>
      </sec>
      <sec id="article-688.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>There is no cure for HSV-2; early identification of symptoms and prompt institution of pharmacotherapy can lead to early suppression of viral replication. Abstinence during known viral shedding can decrease the risk of transmission to a seronegative partner. The herpes viruses as a family are responsible for significant neurological morbidity, and unfortunately, HSV-2 persists in the seropositive individual for a lifetime.</p>
      </sec>
      <sec id="article-688.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Genital HSV-2 infection is known to be associated with an increased risk of HIV infection. As a result, be aware that testing for HIV infection may alter the treatment of HSV-2.<xref ref-type="bibr" rid="article-688.r22">[22]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Untreated HSV-2 can cause meningitis; however, any part of the nervous system may be affected by this virus.</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Aseptic meningitis occurs in 36% of women and 13% of men, leading to the hospitalization of a percentage of inflicted persons. During the prodrome of genital herpes and herpetic eruption, as discussed above, affected individuals may experience more systemic symptoms such as headaches, neck stiffness, and low-grade fever. Such symptoms should lead to immediate lumbar puncture with an analysis of the CSF, often revealing a lymphocytic pleocytosis. While the CSF can be sent for viral culture, PCR is the recommended diagnostic modality.<xref ref-type="bibr" rid="article-688.r8">[8]</xref>&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute retinal necrosis - presents with a unilateral or bilateral red eye(s), periorbital pain, and impaired visual acuity. Examination reveals episcleritis or scleritis and necrosis with retinal detachment. It may occur with HSV-2 meningoencephalitis.<xref ref-type="bibr" rid="article-688.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-688.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Key educational facts to consider are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Condom use is recommended.</p>
          </list-item>
          <list-item>
            <p>Abstain from sexual activity during periods of known active viral shedding (visible lesions).</p>
          </list-item>
          <list-item>
            <p>Consider prophylactic suppressive therapy if frequent sexual activity is likely to occur.<xref ref-type="bibr" rid="article-688.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-688.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>HSV cannot be cured, but suppressive therapy can help prevent the spread to seronegative individuals.</p>
          </list-item>
          <list-item>
            <p>HSV has been associated with HIV infection, and thus, patients with a new diagnosis of HSV should have full STI workups performed.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-688.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The primary care physician or provider will often be the first one to diagnose and treat HSV-2 infections. However, an interprofessional team approach is the optimal means to address this condition.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Early identification of the classical vesicular lesions can lead to prompt treatment and potentially prevent spread to seronegative individuals.</p>
          </list-item>
          <list-item>
            <p>The interprofessional healthcare team, including the medical assistants and nursing staff, is pivotal in educating patients on preventing unnecessary spread. This should be documented and communicated to the treating physician.</p>
          </list-item>
          <list-item>
            <p>Utilizing network public health officials can help dispense information and track STIs in the area, leading to early identification in patients who may be otherwise asymptomatic.</p>
          </list-item>
          <list-item>
            <p>Pharmacists review medications, verify dosing, check for interactions, and inform patients about use and potential side effects. They also may be involved in purchasing condoms and can make patient recommendations.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-688.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=688&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=688">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/herpes-simplex-type-2/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=688">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/688/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=688">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-688.s17">
        <fig id="article-688.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Herpes Simplex <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="herpes__simplex" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-688.s18">
        <fig id="article-688.image.f2" position="float" orientation="portrait">
          <caption>
            <p>This photograph depicted a close view of a patient&#x02019;s vulva, revealing evidence of an outbreak of herpes genitalis, which had manifested as a pustular-vesicular rash around the vaginal introitus due to the herpes simplex virus type-2 (HSV-2) virus. Contributed from the CDC/ Susan Lindsley (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="5408_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-688.s19">
        <fig id="article-688.image.f3" position="float" orientation="portrait">
          <caption>
            <p>This image depicts a close view of a patient&#x02019;s penile shaft, highlighting the presence of a crop of erythematous vesiculopapular lesions, which were determined to have been caused by a herpes genitalis outbreak. Genital herpes is a sexually transmitted disease caused by the herpes simplex viruses type-1 (HSV-1), and type-2 (HSV-2), however, most genital herpes is caused by HSV-2. Symptoms typically include one or more blisters on or around the genitals or rectum. Contributed from the CDC/ Susan Lindsley (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="6480_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-688.s20">
        <fig id="article-688.image.f4" position="float" orientation="portrait">
          <caption>
            <p>This was an outbreak of herpes genitalis, which had manifested as blistering on the underside of the penile shaft, just proximal to the corona of the glans, which was due to the herpes simplex 2 (HSV-2) virus, otherwise referred to as genital herpes. Sexually transmitted herpes simplex HSV-2, typically causes one or more blisters to form on, or around the genitals or rectum, which break, leaving tender ulcers that may take 2 to 4-weeks to heal after making their initial appearance. Contributed from the CDC/ Susan Lindsley (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="15822_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-688.s21">
        <fig id="article-688.image.f5" position="float" orientation="portrait">
          <caption>
            <p>This image depicts a close view of a female&#x02019;s perineum, revealing what had been an outbreak of herpes genitalis, which had manifested as blistering around the vaginal introitus due to the herpes simplex 2 (HSV-2) virus, otherwise referred to as genital herpes. Sexually transmitted herpes simplex HSV-2, typically causes one or more blisters to form on, or around the genitals or rectum, which break, leaving tender ulcers that may take 2 to 4-weeks to heal after making their initial appearance. Contributed from the CDC/ Susan Lindsley (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="15820_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-688.s22">
        <title>References</title>
        <ref id="article-688.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Workowski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>GA</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Sexually transmitted diseases treatment guidelines, 2015.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>05</day>
            <volume>64</volume>
            <issue>RR-03</issue>
            <fpage>1</fpage>
            <page-range>1-137</page-range>
            <pub-id pub-id-type="pmid">26042815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whitley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baines</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical management of herpes simplex virus infections: past, present, and future.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">30443341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sauerbrei</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Herpes Genitalis: Diagnosis, Treatment and Prevention.</article-title>
            <source>Geburtshilfe Frauenheilkd</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>12</issue>
            <fpage>1310</fpage>
            <page-range>1310-1317</page-range>
            <pub-id pub-id-type="pmid">28017972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heitman</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Justus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fife</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Herpes virus type 2 infection and genital symptoms in primary care patients.</article-title>
            <source>Sex Transm Dis</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>416</fpage>
            <page-range>416-21</page-range>
            <pub-id pub-id-type="pmid">16601657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anzivino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fioriti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mischitelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bellizzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barucca</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chiarini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pietropaolo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention.</article-title>
            <source>Virol J</source>
            <year>2009</year>
            <month>Apr</month>
            <day>06</day>
            <volume>6</volume>
            <fpage>40</fpage>
            <pub-id pub-id-type="pmid">19348670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McQuillan</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010.</article-title>
            <source>J Infect Dis</source>
            <year>2014</year>
            <month>Feb</month>
            <day>01</day>
            <volume>209</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-33</page-range>
            <pub-id pub-id-type="pmid">24136792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2010</year>
            <month>Apr</month>
            <day>23</day>
            <volume>59</volume>
            <issue>15</issue>
            <fpage>456</fpage>
            <page-range>456-9</page-range>
            <pub-id pub-id-type="pmid">20414188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berger</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Houff</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neurological complications of herpes simplex virus type 2 infection.</article-title>
            <source>Arch Neurol</source>
            <year>2008</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>596</fpage>
            <page-range>596-600</page-range>
            <pub-id pub-id-type="pmid">18474734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fatahzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>737</fpage>
            <page-range>737-63; quiz 764-6</page-range>
            <pub-id pub-id-type="pmid">17939933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leinweber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kerl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Histopathologic features of cutaneous herpes virus infections (herpes simplex, herpes varicella/zoster): a broad spectrum of presentations with common pseudolymphomatous aspects.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-8</page-range>
            <pub-id pub-id-type="pmid">16330942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;er</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herder</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Herpes folliculitis: clinical, histopathological, and molecular pathologic observations.</article-title>
            <source>Br J Dermatol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>154</volume>
            <issue>4</issue>
            <fpage>743</fpage>
            <page-range>743-6</page-range>
            <pub-id pub-id-type="pmid">16536821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Genital herpes simplex virus infections: clinical manifestations, course, and complications.</article-title>
            <source>Ann Intern Med</source>
            <year>1983</year>
            <month>Jun</month>
            <volume>98</volume>
            <issue>6</issue>
            <fpage>958</fpage>
            <page-range>958-72</page-range>
            <pub-id pub-id-type="pmid">6344712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnston</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Magaret</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Selke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Herpes simplex virus viremia during primary genital infection.</article-title>
            <source>J Infect Dis</source>
            <year>2008</year>
            <month>Jul</month>
            <day>01</day>
            <volume>198</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-4</page-range>
            <pub-id pub-id-type="pmid">18471083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Gardella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Malm</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Prober</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Forsgren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krantz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Arvin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Yasukawa</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Corey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes.</article-title>
            <source>Acta Obstet Gynecol Scand</source>
            <year>2007</year>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>523</fpage>
            <page-range>523-9</page-range>
            <pub-id pub-id-type="pmid">17464578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Preiksaitis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferenczy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romanowski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The laboratory diagnosis of herpes simplex virus infections.</article-title>
            <source>Can J Infect Dis Med Microbiol</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-8</page-range>
            <pub-id pub-id-type="pmid">18159535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slomka</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Current diagnostic techniques in genital herpes: their role in controlling the epidemic.</article-title>
            <source>Clin Lab</source>
            <year>2000</year>
            <volume>46</volume>
            <issue>11-12</issue>
            <fpage>591</fpage>
            <page-range>591-607</page-range>
            <pub-id pub-id-type="pmid">11109508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poole</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Antiviral Therapies for Herpesviruses: Current Agents and New Directions.</article-title>
            <source>Clin Ther</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>1282</fpage>
            <page-range>1282-1298</page-range>
            <pub-id pub-id-type="pmid">30104016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paz-Bailey</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ramaswamy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hawkes</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Geretti</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Herpes simplex virus type 2: epidemiology and management options in developing countries.</article-title>
            <source>Sex Transm Infect</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-22</page-range>
            <pub-id pub-id-type="pmid">17098770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schnitzler</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Essential Oils for the Treatment of Herpes Simplex Virus Infections.</article-title>
            <source>Chemotherapy</source>
            <year>2019</year>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">31234166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuhmacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reichling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schnitzler</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro.</article-title>
            <source>Phytomedicine</source>
            <year>2003</year>
            <volume>10</volume>
            <issue>6-7</issue>
            <fpage>504</fpage>
            <page-range>504-10</page-range>
            <pub-id pub-id-type="pmid">13678235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schnitzler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reichling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture.</article-title>
            <source>Pharmazie</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>343</fpage>
            <page-range>343-7</page-range>
            <pub-id pub-id-type="pmid">11338678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Whitworth</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.</article-title>
            <source>AIDS</source>
            <year>2006</year>
            <month>Jan</month>
            <day>02</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-83</page-range>
            <pub-id pub-id-type="pmid">16327322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-688.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <article-title>Summaries for patients. Condom use and genital herpes.</article-title>
            <source>Ann Intern Med</source>
            <year>2005</year>
            <month>Nov</month>
            <day>15</day>
            <volume>143</volume>
            <issue>10</issue>
            <fpage>I40</fpage>
            <pub-id pub-id-type="pmid">16287786</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
